Brief: Brickell Biotech Selected For A Late-Breaking Oral Presentation Of Us Phase 3 Pivotal Cardigan I And Cardigan Ii Study Results For Sofpironium Bromide Gel, 15% At The 2022 Aad Annual Meeting
10/03/2022 14:08
March 10 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH SELECTED FOR A LATE-BREAKING ORAL
PRESENTATION
OF US PHASE 3 PIVOTAL CARDIGAN I AND CARDIGAN II STUDY RESULTS
FOR SOFPIRONIUM BROMIDE GEL, 15% AT THE 2022 AAD ANNUAL MEETING
Source text for Eikon: ID:nGNX8Q6xC6
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx